Skip to content Skip to footer

FDA Approval for Enmetazobactam: A New Era in Treating Complicated Urinary Tract Infections

The Food and Drug Administration (FDA) has granted a New Drug Approval (NDA) to Orchid Pharma’s Enmetazobactam (Exblifep), a newfound solution to complicated urinary tract infections (cUTIs). This comes as a move towards combatting the growing problem of antimicrobial resistance. The approval was facilitated by enmetazobactam’s status as a Qualified Infectious Disease Product, which offers the drug a window for priority review by the FDA.

The pivotal approval proceeded a global phase 3 trial where the drug demonstrated favourable results in managing cUTIs, a common ailment that affects approximately 3.6 US patients, requiring therapy. Symptoms often include chills, fever, back pain, flank pain, malaise and costo-vertebral angle pain or tenderness. Acute pyelonephritis, an inflammation resulting from an ascending UTI from the bladder to the kidneys, is among the types of cUTIs addressed in these trials.

In a detailed review of the phase 3 trial, 1034 participants were given either cefepime and enmetazobactam or piperacillin and tazobactam, revealing higher success rates with the former drug combination. This introduces to the healthcare landscape an effective, alternative treatment methodology in handling cUTIs, particularly in the age of rising antimicrobial resistance. The FDA’s stamp of approval concludes in the drug’s impending launch in the US market.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]